For the quarter ending 2025-09-30, ACAD had $4,359K increase in cash & cash equivalents over the period. $73,900K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 71,779 | 45,653 |
| Stock-based compensation | 13,180 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | 1,102 | 3,652 |
| Amortization of intangible assets | 2,723 | 5,444 |
| Depreciation | 227 | 442 |
| Accounts receivable, net | 8,345 | 8,766 |
| Interest and other receivables | 11,401 | 6,225 |
| Inventory | -1,248 | 14,553 |
| Prepaid expenses | 8,121 | -2,934 |
| Other assets | 700 | 1,306 |
| Operating lease right-of-use assets | -2,212 | -4,259 |
| Accounts payable | 1,650 | 3,905 |
| Accrued liabilities | 27,776 | 21,350 |
| Operating lease liabilities | -2,179 | -1,418 |
| Long-term liabilities | -14,659 | 10,492 |
| Net cash provided by operating activities | 74,288 | 84,279 |
| Purchases of investment securities | 204,553 | 330,398 |
| Sale and maturity of investment securities | 125,589 | 262,190 |
| Intangible assets | 0 | 98,838 |
| Purchases of property and equipment | 388 | 297 |
| Net cash used in investing activities | -79,352 | -167,343 |
| Proceeds from issuance of common stock, net of issuance costs | 9,423 | 17,794 |
| Net cash provided by financing activities | 9,423 | 17,794 |
| Effect of exchange rate changes on cash | 0 | 19 |
| Net decrease in cash, cash equivalents and restricted cash | 4,359 | -65,251 |
| Cash and cash equivalents at beginning of period | 328,359 | - |
| Cash and cash equivalents at end of period | 267,467 | - |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)